GE HealthCare Technologies (GEHC) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: GEHC's preliminary Q2 release (July 23) already confirmed a revenue beat ($5,295M vs. $5,267M consensus) and Adjusted EPS "ahead of prior expectation," making this a setup to beat — the key swing factor is whether management raises full-year EPS guidance and provides a credible Flyrcado ramp update.

The bar heading into Q2 was manageable: consensus sat at $5,267M in revenue (3.3% organic growth) and ~$1.04 Adjusted EPS, both below the company's own Q2 guidance of 3–4% organic growth and low-single-digit EPS decline YoY. GEHC's July 23 preliminary release already cleared that bar — reporting $5,295M in revenue (+5.7% reported, +3.5% organic) and flagging Adjusted EPS "ahead of prior expectation," which effectively pre-announces a beat before the formal call. Management's posture has shifted more constructive since Q1: at the Jefferies conference (June 3), CFO Saccaro signaled that oil/freight costs — roughly half the $250M gross inflation headwind — were tracking at or below the levels assumed in guidance, providing a potential tailwind to the Q2 print. Estimate revisions have been broadly stable since the post-Q1 reset, with FY2026 Adjusted EPS consensus at $4.88 — essentially flat to the $4.80–$5.00 guidance range midpoint — suggesting the Street has not yet priced in any upside from easing inflation or tariff tailwinds. The stock has recovered ~8% since the Q1 selloff (vs. +4.7% for IHI and +4.1% for SPY), but still trades well below pre-Q1 levels, implying the market has not fully priced in a beat. The single biggest wildcard is the PCS strategic review: management flagged potential portfolio alternatives at Q1, and any concrete announcement — sale, spin, or restructuring — could be a material catalyst in either direction.

2. KPIs & Consensus Expectations

Key Takeaway: The bar is low — GEHC's preliminary release already confirmed a revenue beat and EPS ahead of expectation. The bigger swing factor is the Adjusted EPS magnitude and whether management raises FY2026 guidance, particularly on the profit line where the Q1 cut created the most investor anxiety.

Table 1 — Q2 2026 Current Quarter Snapshot

Sources: Visible Alpha consensus and actuals data. Q2 2026 preliminary revenue of $5,295M confirmed via GEHC July 23, 2026 earnings release (8-K EX-99). Consensus estimates as of July 28, 2026. Guidance per Q1 2026 earnings call (April 29, 2026). Note: Q2 2026 Adj. EPS actual not yet disclosed in preliminary release; formal figures to be reported July 29, 2026.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

KPI 1: Total Revenue

KPI 2: Adjusted EPS (Diluted Operating)

Pattern: GEHC has beaten revenue consensus in 5 of the last 6 quarters (missing narrowly in Q2–Q4 2024 by <1%). On Adjusted EPS, the company beat in 7 of 8 quarters — often by wide margins — before the Q1 2026 miss driven by the discrete PDx supplier issue and new inflation headwinds. The preliminary Q2 release signals a return to the beat pattern on both metrics.

Source: Visible Alpha consensus and actuals data.

3. Guidance & Commentary Evolution

Key Takeaway: Full-year revenue guidance is unchanged at 3–4% organic growth, but profit guidance was cut at Q1 (April 29). Since then, management tone has shifted more constructive — freight/oil costs are tracking below guidance assumptions, Flyrcado is accelerating, and the tariff regime is broadly neutral — setting up a potential guidance raise on the profit line at Q2.

Sources: Q1 2026 earnings call (April 29, 2026); BofA Global Healthcare Conference (May 12, 2026); Jefferies Global Healthcare Conference (June 3, 2026); GEHC preliminary Q2 2026 earnings release (July 23, 2026); Visible Alpha consensus data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been broadly stable since the post-Q1 reset, with FY2026 EPS consensus essentially flat to the guidance midpoint. The lack of upward revision despite improving freight/oil cost trends and a strong Q2 preliminary suggests the Street has not yet priced in potential guidance upside — creating asymmetric risk to the upside if management raises the profit outlook.

Estimates have been remarkably stable since the post-Q1 reset — essentially no revision in either direction over the past ~3 months. This flat trajectory, combined with the preliminary Q2 beat and improving cost trends (freight/oil below guidance assumptions per CFO at Jefferies), suggests the Street has been waiting for the formal Q2 print before revising. A guidance raise on the FY2026 EPS line would likely trigger meaningful upward revisions.

Source: Visible Alpha consensus data. Baseline as of May 6, 2026 (5 trading days post Q1 2026 earnings). Current consensus as of July 28, 2026.

5. Stock Performance

Key Takeaway: GEHC has outperformed both IHI (+4.7%) and the S&P 500 (+4.1%) since the Q1 2026 earnings selloff, recovering ~7.8% from the April 29 close — driven primarily by insider buying conviction signals and improving cost trend commentary at conferences, rather than estimate revisions (which have been flat).

GEHC vs. IHI (iShares U.S. Medical Devices ETF) vs. S&P 500 (SPY) — Indexed to 100 at April 29, 2026 (Q1 2026 earnings date). Source: Yahoo Finance.

Since the Q1 2026 earnings selloff on April 29, GEHC has recovered approximately 7.8% (to $64.11 as of July 29 pre-market), outpacing IHI (+4.7%) and SPY (+4.1%). The recovery was not driven by estimate revisions — which have been essentially flat — but rather by: (1) a cluster of insider open-market purchases by the CEO, CFO, and multiple directors in late April/early May at prices near the post-earnings lows; (2) improving management tone at the BofA (May 12) and Jefferies (June 3) conferences, particularly around freight/oil cost trends tracking below guidance assumptions; and (3) the July 23 preliminary release confirming a Q2 beat. The stock briefly touched $66 in early June before pulling back on broader market weakness, and has re-accelerated into the formal Q2 print. At ~$64, GEHC trades at approximately 13x FY2026 consensus EPS of $4.88 — a discount to medtech peers — suggesting multiple expansion is possible if management raises guidance.

Note: IHI (iShares U.S. Medical Devices ETF) used as the sector benchmark, appropriate for GEHC's medical imaging and diagnostics sub-sector. Material events marked: BofA Healthcare Conference (May 12), Jefferies Healthcare Conference (June 3), Q2 Preliminary Release (July 23).

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the July 23 preliminary release confirming a Q2 beat on both revenue and EPS — combined with the CFO departure announcement, which introduces a leadership transition risk heading into the formal call.

• July 23, 2026 — Q2 2026 Preliminary Results & CFO Departure (8-K): GEHC pre-announced Q2 revenue of $5,295M (+5.7% reported, +3.5% organic) and flagged Adjusted EPS "ahead of prior expectation." Simultaneously, the company announced CFO James Saccaro's departure with an interim successor named. The revenue beat is unambiguously positive; the CFO transition introduces uncertainty around capital allocation messaging and guidance credibility on the Q2 call.
• July 8, 2026 — Q2 Earnings Date Confirmed: GEHC confirmed July 29, 2026 as the Q2 2026 earnings call date. No incremental guidance or business update provided.
• June 3, 2026 — Jefferies Global Healthcare Conference (CFO Saccaro): CFO provided key Q2 updates: (1) Flyrcado annual run rate doubled from ~$25M in Q1 to ~$50M in Q2, with customer base up ~50% since year-start; (2) oil/freight costs tracking at or below guidance assumptions, representing potential upside to profit guidance; (3) Section 122 tariffs expected to expire in July and likely be replaced by a new regime (possibly Section 232), with current guidance conservatively assuming tariffs run through year-end; (4) next Flyrcado weekly dose data point to be provided in July.
• May 12, 2026 — BofA Global Healthcare Conference (CFO Saccaro): CFO used notably direct language on PCS — Q1 organic revenue decline and margin level represent "not an acceptable threshold of performance"; strategic alternatives being evaluated across all PCS components. Also provided granular inflation breakdown: ~$100M from freight/logistics (Middle East conflict), ~$50M from other commodities (helium), ~$100M from memory chip inflation. Confirmed Q2 buyback activity to be disclosed on Q2 call.
• May 11, 2026 — Annual Shareholder Meeting: All proposals approved; new Lead Director and Committee Chair appointed. No material business update.
• Late April / Early May 2026 — Cluster of Insider Open-Market Purchases: CEO Arduini (4,169 shares, Apr 30), CFO Saccaro (3,310 shares, May 1), Director Culp (80,805 shares via holding company, May 6), Director Stromberg (1,000 shares, May 6), Director Yang Watkin (1,000 shares, May 8), Director Lobo (10,000 shares, May 22), and Director Hochman (1,618 shares, May 12) all purchased shares in the open market following the post-Q1 selloff. CFO explicitly framed purchases as driven by an intrinsic value DCF model showing shares at a substantial discount to intrinsic value.
• April 29, 2026 — Q1 2026 Earnings (Last Formal Print): Revenue beat ($5,131M vs. $5,024M consensus); Adj. EPS missed ($0.99 vs. $1.06 consensus) due to discrete PDx supplier quality issue and new inflation headwinds. Full-year profit and FCF guidance cut. Stock declined meaningfully on the day. Segment restructuring announced: Imaging + AVS combined into Advanced Imaging Solutions (AIS); PCS separated as standalone segment.
• Q1 2026 — Intelerad Acquisition Closed: GEHC closed the Intelerad acquisition, advancing its cloud-enabled enterprise imaging strategy. Contributed ~$62M to Q2 2026 revenue per the preliminary release.
• Q1 2026 — Photonova Spectra FDA & Japan Clearances: Photon-counting CT received FDA clearance in late March 2026 and Japan clearance in Q1. Pipeline funnel already well in excess of $100M; revenue contribution expected to begin H1 2027. Positioned as a "blue ocean" new market opportunity.
• Q1 2026 — Omnipaque Generic Competition (Amneal Iohexol Launch): First generic iohexol entered the market. Management confirmed the launch and expected strategy were fully incorporated into 2026 guidance and mid-term targets. Supply consistency, product quality, and multi-SKU portfolio cited as durable competitive advantages.

7. Peer Commentaries — Q2 2026 Read-Throughs

Key Takeaway: Peer Q2 2026 earnings calls from Philips (PHG), Danaher (DHR), Abbott (ABT), and Intuitive Surgical (ISRG) collectively paint a constructive picture for GEHC: hospital capital spending remains healthy in North America and Europe, imaging demand is robust, China is stabilizing (not worsening), and tariff refunds provided a one-time margin tailwind for some peers. The read-through is broadly positive for GEHC's Q2 print.

Philips (PHG) — Q2 2026 Earnings (July 28, 2026)

• Hospital capital spending remains healthy in North America and Europe: Philips reported "healthy patient volumes, procedural growth, and sustained capital investment by larger health systems" in North America. European health systems are "investing in productivity, digitization, and in modernizing care delivery." Philips was named Healthtrust's 2026 Capital Supplier of the Year. Read-through for GEHC: Confirms the favorable hospital capex backdrop that GEHC management has consistently cited in surveys. Supports GEHC's imaging order growth and backlog conversion thesis.
• Imaging demand robust; MRI and CT leading: Philips' Diagnosis & Treatment segment grew comparable sales +2.4%. MRI "performed strongly" driven by differentiated portfolio. CT platform innovations (Rampart, Narita T) began contributing to revenue. Precision diagnosis delivered "strong order growth, including double-digit growth outside of China." Image-guided therapy delivered high single-digit growth for the 22nd consecutive quarter. Read-through for GEHC: Broad-based imaging demand is intact. GEHC's Imaging segment (consensus $2,370M, +7.5% YoY) should benefit from the same demand tailwinds, with additional upside from new product launches (Photonova Spectra, next-gen MR).
• China: broadly in line with expectations, not worsening: Philips noted China market conditions "developed broadly in line with our expectations" in Q2. Health systems continued to face a challenging environment due to centralized procurement and subdued hospital investment, but Philips now expects China to be "broadly stable" for the full year. CT Spectrum showed "real good momentum and positive orders" in China. Read-through for GEHC: Consistent with GEHC's own guidance (China modeled down for FY2026 but improving predictability). No incremental deterioration is a positive signal.
• Tariff refund provided a one-time margin tailwind: Philips received "virtually all of the tariff amount claimed" in Q2, boosting adjusted EBITDA margin to 16.4% (vs. 12.2% underlying). Philips expects "high single-digit cost inflation for the full year 2026" with greater impact in H2 as higher-cost inventory is recognized. Read-through for GEHC: GEHC does not have a comparable tariff refund dynamic, but the Philips commentary confirms that tariff/inflation headwinds are an industry-wide phenomenon — not GEHC-specific. GEHC's Section 122 tariff expiry (July) could provide a modest tailwind if replaced by a more favorable regime.
• Order intake declined 1% in Q2 (timing-driven, not demand): Philips' overall order intake declined 1% after six consecutive quarters of growth, attributed to "certain larger monitoring orders specifically moved to Q3" — not a deterioration in underlying demand. Solid order growth expected in Q3, returning to "mid-single digit range." Read-through for GEHC: Timing-driven order lumpiness is a known dynamic in medtech capital equipment. GEHC's record $21.8B backlog and 1.07x book-to-bill in Q1 provide strong visibility regardless of quarter-to-quarter order timing.

Danaher (DHR) — Q2 2026 Earnings (July 21, 2026)

• Diagnostics demand healthy; mid-single-digit growth outside China: DHR's diagnostics segment core revenue grew +2% YoY (+5% ex-respiratory). Clinical diagnostics businesses grew mid-single digits globally, with high single-digit growth outside China. Beckman Coulter Diagnostics grew mid-single digits with solid immunoassay revenue and install base growth. Read-through for GEHC: Confirms healthy underlying diagnostics demand, supportive for GEHC's PDx segment (consensus $798M, +9.5% YoY) which includes Flyrcado and Omnipaque.
• China diagnostics improving sequentially; VBP headwinds moderating: DHR noted China diagnostics "improved sequentially" as the impact of volume-based procurement changes that began in late 2020 started to moderate. Beckman Coulter saw declines in China "begin to moderate as pricing stabilized and volumes improved." DHR expects China policy headwinds to "continue to lessen in Q3 and Q4." Read-through for GEHC: Positive signal for GEHC's China trajectory. GEHC has modeled China down for FY2026 but cited improving predictability and win rates — DHR's commentary suggests the broader China healthcare market is stabilizing, which could provide upside to GEHC's conservative China assumption.
• Underlying order trends robust; mid-teens growth in consumables and equipment: DHR reported "mid-teens order growth in both consumables and equipment" with demand from large pharma/biopharma remaining healthy and improved biotech funding supporting funnel activity. Academic and government markets "largely stabilized." Read-through for GEHC: Strong equipment order trends are a positive read-through for GEHC's imaging and ultrasound capital equipment demand.
• Masimo acquisition closed (patient monitoring read-through for PCS): DHR closed the Masimo acquisition in early June, with Masimo delivering high single-digit revenue growth in H1 2026. Masimo received FDA 510(k) clearance for an AI-enabled opioid-induced respiratory depression detection solution. Read-through for GEHC: Masimo's strong performance in patient monitoring is a mixed read-through for GEHC's PCS segment — it confirms demand exists in the space, but also signals that GEHC faces a well-capitalized competitor. The PCS strategic review remains a key overhang.

Abbott (ABT) — Q2 2026 Earnings (July 16, 2026)

• U.S. hospital testing volumes held up; no ACA disenrollment impact: Abbott CEO Ford explicitly addressed investor concerns about ACA disenrollment, stating testing volumes in the U.S. "have held up very well, not seeing a decline, including in the states that we've seen the highest level of ACA disenrollment." U.S. core lab business accelerated to +7.5% growth in Q2. Hospital labs (instruments and reagents) grew +13% in Q2. Read-through for GEHC: Directly addresses a key investor concern about U.S. healthcare demand. Strong hospital lab volumes support GEHC's imaging and diagnostics demand thesis. Ford's comment that "healthcare demand is just going to continue to accelerate" as the population ages is a structural positive for GEHC's end markets.
• Diagnostic test volumes are a reliable barometer of healthcare demand: Abbott noted that "diagnostic test results inform approximately 70% of all healthcare decisions" and that its test volume data "continues to reflect strong and stable demand for testing" — characterizing this as evidence of "durable underlying demand for healthcare, not just in the US but globally." Read-through for GEHC: Supports GEHC's PDx segment demand outlook and the broader thesis that healthcare utilization is resilient despite macro uncertainty.
• China still declining but at a much lower rate in H2: Abbott is "still forecasting a decline in the China business, but much, much lower mid-single digits" for H2 2026, after experiencing ~30% declines for five quarters due to VBP. Read-through for GEHC: Consistent with GEHC's own China guidance (modeled down for FY2026). The trajectory of improvement at Abbott suggests GEHC's China business may also be approaching a stabilization point.
• Medical devices segment grew +8.5%; procedure volumes resilient: Abbott's medical devices segment grew +8.5% in Q2, led by electrophysiology (low-teens) and rhythm management (high single-digit). Abbott raised full-year guidance to 6.5–7.5% comparable sales growth and EPS of $5.45–$5.60. Read-through for GEHC: Broad medtech demand remains healthy. Abbott's guidance raise is a positive signal for the sector heading into GEHC's print.

Intuitive Surgical (ISRG) — Q2 2026 Earnings (July 16, 2026)

• U.S. hospital capital environment stable; pipeline healthy: ISRG reported a "strong capital quarter" with 267 U.S. system placements (+24% YoY). CEO noted the "U.S. capital environment, at least in our experience, has been stable for some time now" and that the pipeline "has been healthy, largely due to interest in DaVinci five." ~70% of U.S. systems are under leasing arrangements, providing flexibility for capital-constrained customers. Read-through for GEHC: Confirms the stable U.S. hospital capital spending environment that GEHC management has cited in surveys. Leasing/financing flexibility is also a tool GEHC uses to support imaging equipment placements.
• Some customers expressing caution on ACA enrollment, but no pipeline impact yet: ISRG noted "some customers express caution over ACA enrollment trends, but we haven't seen that impact our pipeline, at least to this point." U.S. DaVinci procedure growth moderated from recent trends, "predominantly in procedures that can be deferred," with some attributing this to changes in patient coverage dynamics. Read-through for GEHC: A mild caution flag for elective/deferrable procedure volumes, though GEHC's imaging equipment demand is more driven by hospital capital budgets and new product cycles than procedure volumes. The ACA concern has not materialized into order cancellations for ISRG.
• China remains challenging; only 2 systems placed: ISRG placed only 2 systems in China in Q2, continuing to face "lower tender activity, increased domestic robotic competition, and policy-driven pricing pressure." DaVinci five is not yet cleared in mainland China. Read-through for GEHC: ISRG's China challenges are more acute than GEHC's (robotics faces more direct domestic competition and VBP risk). GEHC's China imaging business has shown improving win rates and predictability, suggesting a less severe trajectory.
• Tariff refund provided a $36M pre-tax benefit in Q2: ISRG received a $36M pre-tax benefit from the refund of previously paid IEEPA tariffs. Excluding this, non-GAAP gross margin would have been 68.7%. ISRG continues to expect "higher input costs in certain areas, including freight and semiconductor memory" for full-year 2026. Read-through for GEHC: ISRG's explicit call-out of freight and semiconductor memory as ongoing cost headwinds directly mirrors GEHC's own inflation narrative. The tariff refund dynamic (IEEPA refunds) is relevant — GEHC management noted near-term uncertainty around potential IEEPA refunds at the Jefferies conference, suggesting a similar one-time benefit may be possible.
• Procedure volumes grew +16%; Ion (lung biopsy) up +36%: Total procedures grew +16% with DaVinci up +15% and Ion up +36%. Cardiac procedures accelerated to +39% growth. Strong procedure volumes support recurring instrument and service revenue. Read-through for GEHC: High procedure volumes support demand for imaging equipment used in pre-operative planning and intraoperative guidance (CT, MRI, ultrasound). GEHC's image-guided therapy and interventional imaging products benefit from the same procedure volume tailwinds.

Sources: PHG Q2 2026 Earnings Call (July 28, 2026); DHR Q2 2026 Earnings Call (July 21, 2026); ABT Q2 2026 Earnings Call (July 16, 2026); ISRG Q2 2026 Earnings Call (July 16, 2026). All commentary pertains to Q2 2026 (calendar quarter ended June 30, 2026) and is directly relevant to GEHC's current reporting quarter.

8. Insider Transaction Activity

Key Takeaway: The post-Q1 insider buying cluster is one of the most notable conviction signals in GEHC's history as a public company — CEO, CFO, and multiple directors all purchased shares in the open market within days of the earnings selloff, with CFO Saccaro explicitly citing an intrinsic value DCF model showing shares at a substantial discount. No insider selling has occurred since the Q1 print.

Note: Multiple director equity award grants (Code A) on May 7, 2026 (Culp, Hochman, Lesjak, Lobo, Madden, Stromberg, Yang Watkin) represent routine annual equity compensation, not open-market purchases, and are excluded from the table above. The Bankes disposition (Code F) is a tax withholding on vesting — not a discretionary sale. No open-market sales (Code S) have been filed since the Q1 2026 earnings date. The cluster of open-market buys by the CEO, CFO, and five directors within the first two weeks post-earnings is a strong conviction signal — particularly the CFO's explicit DCF-based rationale and the company's own Q1 buyback of $100M at ~$70/share (well above current levels).

Source: SEC Form 4 filings via Insider Transaction Data.